- Home
- ENX vs BDTX Comparison
ENX vs BDTX Comparison
Compare ENX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- BDTX
- Stock Information
- Founded
- ENX 2002
- BDTX 2014
- Country
- ENX United States
- BDTX United States
- Employees
- ENX N/A
- BDTX N/A
- Industry
- ENX Finance/Investors Services
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENX Finance
- BDTX Health Care
- Exchange
- ENX Nasdaq
- BDTX Nasdaq
- Market Cap
- ENX 169.0M
- BDTX 181.4M
- IPO Year
- ENX N/A
- BDTX 2020
- Fundamental
- Price
- ENX $9.94
- BDTX $3.88
- Analyst Decision
- ENX
- BDTX Strong Buy
- Analyst Count
- ENX 0
- BDTX 5
- Target Price
- ENX N/A
- BDTX $12.00
- AVG Volume (30 Days)
- ENX 25.4K
- BDTX 1.1M
- Earning Date
- ENX 01-01-0001
- BDTX 11-04-2025
- Dividend Yield
- ENX 3.94%
- BDTX N/A
- EPS Growth
- ENX N/A
- BDTX N/A
- EPS
- ENX 0.16
- BDTX 0.25
- Revenue
- ENX N/A
- BDTX $70,000,000.00
- Revenue This Year
- ENX N/A
- BDTX N/A
- Revenue Next Year
- ENX N/A
- BDTX N/A
- P/E Ratio
- ENX $61.00
- BDTX $15.62
- Revenue Growth
- ENX N/A
- BDTX N/A
- 52 Week Low
- ENX $7.84
- BDTX $1.20
- 52 Week High
- ENX $10.07
- BDTX $4.03
- Technical
- Relative Strength Index (RSI)
- ENX 63.84
- BDTX 69.39
- Support Level
- ENX $9.81
- BDTX $3.62
- Resistance Level
- ENX $9.94
- BDTX $3.87
- Average True Range (ATR)
- ENX 0.07
- BDTX 0.21
- MACD
- ENX -0.02
- BDTX 0.05
- Stochastic Oscillator
- ENX 55.00
- BDTX 89.22
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.